Lung Cancer Drugs in Development to Address Resistance Mutations
Nathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.
Improving Outcomes for Patients With NSCLC and RET Alterations
Nathan A. Pennell, MD, PhD, discusses the importance of developing new RET inhibitors for patients with non–small cell lung cancer.
Goals in the Phase 1 Study of a New RET Inhibitor for NSCLC and MTC
Nathan A. Pennell, MD, PhD, discusses the study design and goals of an ongoing phase 1 trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.
Trial of New RET Inhibitor Aims to Overcome Resistance in NSCLC and MTC
Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.
Evaluating the Role of Molecular Testing in Lung Cancer
Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with <a>lung cancer.</a> He shares his advice on what to do for patients who need therapy immediately, as well.
